Observational studyEuropean journal of neurology2025
Hippocampal Subfields Volume: Another Hint of the Continuum Between CAA and AD?
Observational study in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04204642 (SEarchiNg biomarkErs Cerebral Amyloid Angiopathy), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA): Italian Network for the Study of CAA
Who cites it
2 citing papers in PubMed.
- Hippocampal Subfields Volume: Another Hint of the Continuum Between CAA and AD?European journal of neurology · 2025Observational
- Cerebral amyloid angiopathy: a narrative review.Frontiers in aging neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveThis study investigates whether cerebral amyloid angiopathy (CAA) patients with Alzheimer's disease (AD)-like CSF profile exhibit radiological features characteristic of AD, specifically reduced hippocampal and amygdala volumes.
methodsFrom a database of 162 probable CAA cases (Boston 2.0 criteria) at the Fondazione IRCCS Istituto Neurologico Carlo Besta, 44 patients underwent CSF analysis (Aβ42, Aβ40, and p-Tau181) and brain MRI with volumetric T1 sequences. Participants with CSF levels of Aβ42 < 640 pg/mL and p-Tau181 > 56.5 pg/mL were classified as CAA/AD+; otherwise, as CAA/AD-. Hippocampal and amygdala volumes were assessed using volBrain software, and statistical analyses included t-tests and Mann-Whitney U tests.
resultsCAA/AD+ patients (n = 22) were older than CAA/AD- (median age: 73 vs. 67 years, p = 0.006). No significant differences were observed in total hippocampal or amygdala volumes. However, Cornu Ammonis 2-3 (CA2-CA3) hippocampal subfield volume and its ratio to total intracranial volume were significantly lower in CAA/AD+ patients (0.29 vs. 0.35, p = 0.015; 0.02 vs. 0.03, p = 0.011). DISCUSSION: We found that CA2-CA3 atrophy, potentially linked to tau pathology, was a distinctive feature in our CAA/AD+ cohort. While total hippocampal and amygdala volumes did not differentiate these groups, CA2-CA3 volume may serve as a radiological marker for identifying biological overlaps between CAA and AD. Future studies should validate these findings and explore their implications for neurodegenerative diseases.
trial registrationClinicalTrials.gov Identifier: NCT04204642.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.